Stephanie M Dillon1, Jon Kibbie1, Eric J Lee1, Kejun Guo1, Mario L Santiago1, Gregory L Austin2, Sara Gianella3, Alan L Landay4, Andrew M Donovan1, Daniel N Frank1,5, Martin D McCARTER6, Cara C Wilson1. 1. Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 2. Department of Gastroenterology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 3. Division of Infectious Diseases, University of California, San Diego, La Jolla, California, USA. 4. Department of Immunology-Microbiology, Rush University Medical Center, Chicago, Illinois, USA. 5. University of Colorado Microbiome Research Consortium, Aurora, Colorado, USA. 6. Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Abstract
OBJECTIVE: Gut microbial translocation is a major driving force behind chronic immune activation during HIV-1 infection. HIV-1-related intestinal dysbiosis, including increases in mucosa-associated pathobionts, may influence microbial translocation and contribute to mucosal and systemic inflammation. Thus, it is critical to understand the mechanisms by which gut microbes and their metabolic products, such as butyrate, influence immune cell function during HIV-1 infection. DESIGN: A cross-sectional study was performed to compare the relative abundance of butyrate-producing bacterial (BPB) species in colonic biopsies and stool of untreated, chronic HIV-1-infected (n = 18) and HIV-1-uninfected (n = 14) study participants. The effect of exogenously added butyrate on gut T-cell activation and HIV-1 infection was evaluated using an ex-vivo human intestinal cell culture model. METHODS: Species were identified in 16S ribosomal RNA sequence datasets. Ex-vivo isolated lamina propria mononuclear cells were infected with C-C chemokine receptor type 5-tropic HIV-1Bal, cultured with enteric gram-negative bacteria and a range of butyrate doses, and lamina propria T-cell activation and HIV-1 infection levels measured. RESULTS: Relative abundance of total BPB and specifically of Roseburia intestinalis, were lower in colonic mucosa of HIV-1-infected versus HIV-1-uninfected individuals. In HIV-1-infected study participants, R. intestinalis relative abundance inversely correlated with systemic indicators of microbial translocation, immune activation, and vascular inflammation. Exogenous butyrate suppressed enteric gram-negative bacteria-driven lamina propria T-cell activation and HIV-1 infection levels in vitro. CONCLUSION: Reductions in mucosal butyrate from diminished colonic BPB may exacerbate pathobiont-driven gut T-cell activation and HIV replication, thereby contributing to HIV-associated mucosal pathogenesis.
OBJECTIVE: Gut microbial translocation is a major driving force behind chronic immune activation during HIV-1 infection. HIV-1-related intestinal dysbiosis, including increases in mucosa-associated pathobionts, may influence microbial translocation and contribute to mucosal and systemic inflammation. Thus, it is critical to understand the mechanisms by which gut microbes and their metabolic products, such as butyrate, influence immune cell function during HIV-1 infection. DESIGN: A cross-sectional study was performed to compare the relative abundance of butyrate-producing bacterial (BPB) species in colonic biopsies and stool of untreated, chronic HIV-1-infected (n = 18) and HIV-1-uninfected (n = 14) study participants. The effect of exogenously added butyrate on gut T-cell activation and HIV-1 infection was evaluated using an ex-vivo human intestinal cell culture model. METHODS: Species were identified in 16S ribosomal RNA sequence datasets. Ex-vivo isolated lamina propria mononuclear cells were infected with C-C chemokine receptor type 5-tropic HIV-1Bal, cultured with enteric gram-negative bacteria and a range of butyrate doses, and lamina propria T-cell activation and HIV-1 infection levels measured. RESULTS: Relative abundance of total BPB and specifically of Roseburia intestinalis, were lower in colonic mucosa of HIV-1-infected versus HIV-1-uninfected individuals. In HIV-1-infected study participants, R. intestinalis relative abundance inversely correlated with systemic indicators of microbial translocation, immune activation, and vascular inflammation. Exogenous butyrate suppressed enteric gram-negative bacteria-driven lamina propria T-cell activation and HIV-1 infection levels in vitro. CONCLUSION: Reductions in mucosal butyrate from diminished colonic BPB may exacerbate pathobiont-driven gut T-cell activation and HIV replication, thereby contributing to HIV-associated mucosal pathogenesis.
Authors: Petra Louis; Sylvia H Duncan; Sheila I McCrae; Jacqueline Millar; Michelle S Jackson; Harry J Flint Journal: J Bacteriol Date: 2004-04 Impact factor: 3.490
Authors: J F Vázquez-Castellanos; S Serrano-Villar; A Latorre; A Artacho; M L Ferrús; N Madrid; A Vallejo; T Sainz; J Martínez-Botas; S Ferrando-Martínez; M Vera; F Dronda; M Leal; J Del Romero; S Moreno; V Estrada; M J Gosalbes; A Moya Journal: Mucosal Immunol Date: 2014-11-19 Impact factor: 7.313
Authors: Caleb J Kelly; Leon Zheng; Eric L Campbell; Bejan Saeedi; Carsten C Scholz; Amanda J Bayless; Kelly E Wilson; Louise E Glover; Douglas J Kominsky; Aaron Magnuson; Tiffany L Weir; Stefan F Ehrentraut; Christina Pickel; Kristine A Kuhn; Jordi M Lanis; Vu Nguyen; Cormac T Taylor; Sean P Colgan Journal: Cell Host Microbe Date: 2015-04-09 Impact factor: 21.023
Authors: Mary A Zimmerman; Nagendra Singh; Pamela M Martin; Muthusamy Thangaraju; Vadivel Ganapathy; Jennifer L Waller; Huidong Shi; Keith D Robertson; David H Munn; Kebin Liu Journal: Am J Physiol Gastrointest Liver Physiol Date: 2012-04-19 Impact factor: 4.052
Authors: Collin L Ellis; Zhong-Min Ma; Surinder K Mann; Chin-Shang Li; Jian Wu; Thomas H Knight; Tammy Yotter; Timothy L Hayes; Archana H Maniar; Paolo V Troia-Cancio; Heather A Overman; Natalie J Torok; Anthony Albanese; John C Rutledge; Christopher J Miller; Richard B Pollard; David M Asmuth Journal: J Acquir Immune Defic Syndr Date: 2011-08-15 Impact factor: 3.731
Authors: H-J Epple; T Schneider; H Troeger; D Kunkel; K Allers; V Moos; M Amasheh; C Loddenkemper; M Fromm; M Zeitz; J-D Schulzke Journal: Gut Date: 2008-10-20 Impact factor: 23.059
Authors: Stephanie M Dillon; Moriah J Castleman; Daniel N Frank; Gregory L Austin; Sara Gianella; Andrew C Cogswell; Alan L Landay; Edward Barker; Cara C Wilson Journal: J Acquir Immune Defic Syndr Date: 2017-12-01 Impact factor: 3.731
Authors: Leopoldo N Segal; Jose C Clemente; Yonghua Li; Chunhai Ruan; Jane Cao; Mauricio Danckers; Alison Morris; Sarah Tapyrik; Benjamin G Wu; Philip Diaz; Gregory Calligaro; Rodney Dawson; Richard N van Zyl-Smit; Keertan Dheda; William N Rom; Michael D Weiden Journal: Cell Host Microbe Date: 2017-03-30 Impact factor: 21.023
Authors: Stephanie M Dillon; Kejun Guo; Gregory L Austin; Sara Gianella; Phillip A Engen; Ece A Mutlu; John Losurdo; Garth Swanson; Prachi Chakradeo; Ali Keshavarzian; Alan L Landay; Mario L Santiago; Cara C Wilson Journal: AIDS Date: 2018-07-31 Impact factor: 4.177